Abstract. We previously demonstrated that the α-kinase 1 gene (ALPK1) is a susceptibility locus for chronic kidney disease in individuals with diabetes mellitus (DM) by a genome-wide association study. Although genetic variants of ALPK1 have been associated with chronic kidney disease in individuals with DM, whether ALPK1 is a susceptibility locus for DM has not been elucidated. The purpose of the present study was to investigate a possible association of the rs2074388 (A→G, Asp565Gly) or rs2074379 (A→G, Ile732Met) variants of ALPK1 with type 2 DM in community-dwelling individuals. The study subjects comprised 5,959 community-dwelling individuals (495 subjects with type 2 DM and 5,464 controls) who were recruited to a population-based cohort study in Inabe, Mie, Japan. The comparisons of allele frequencies or genotype distributions using the Chi-square test revealed that the rs2074388 and rs2074379 variants of ALPK1 were significantly associated with type 2 DM (P<0.05). A multivariable logistic regression analysis with adjustment for age, gender, body mass index and smoking status revealed that the rs2074388 (P=0.0051; odds ratio, 1.32) and rs2074379 (P=0.0058; odds ratio, 1.32) variants were significantly associated with type 2 DM. The haplotype analysis of these polymorphisms revealed that the frequency of the major haplotype, A (rs2074388)-A (rs2074379), was significantly lower, whereas that of the minor haplotype G-G was significantly higher in subjects with type 2 DM compared to controls. Thus, ALPK1 may be a susceptible gene for type 2 DM in community-dwelling Japanese individuals.
Introduction
The incidence of type 2 diabetes mellitus (DM) is rapidly increasing and has become one of the most common chronic diseases worldwide (1) . According to recent estimates, the prevalence of type 2 DM will increase to 439 million adults (7.7%) by 2030 (2) . Asia in particular is a major site of emerging epidemics, mainly due to the transition in nutritional habits and changes in lifestyle (2) . Since type 2 DM is associated with an increased incidence of cardiovascular disease and long-term mortality, it imposes a significant economic burden on healthcare wordwide (3, 4) . Furthermore, the contribution of intensive lifestyle intervention or glycemic control to the reduction of cardiovascular mortality remain controversial (5, 6) . Therefore, aggressive disease prevention and early detection should be a global strategy priority.
Family history is one of the major risk factors for type 2 DM (7), suggesting that genetic factors significantly contribute to the development and progression of type 2 DM (8) . To date, genome-wide association studies (GWASs) have identified various loci and ~40 genes associated with predisposition to type 2 DM (9-13); however, the genes that contribute to genetic susceptibility to type 2 DM in Japanese individuals have yet to be definitively identified.
We previously demonstrated that the α-kinase 1 gene (ALPK1) is a susceptibility locus for chronic kidney disease in Japanese individuals with DM by a GWAS (14) . Although genetic variants of ALPK1 have been associated with chronic kidney disease in individuals with DM, whether ALPK1 is a susceptibility locus for DM has not been elucidated. Thus, we conducted an association study for the rs2074388 (A→G, Asp565Gly) or rs2074379 (A→G, Ile732Met) variants of ALPK1 and type 2 DM in community-dwelling Japanese individuals, in order to provide a basis for the personalized prevention of this disease. Genotyping of polymorphisms. Venous blood (5 ml) was collected into tubes containing 50 mmol/l ethylenediaminetetraacetic acid (disodium salt), peripheral blood leukocytes were isolated and genomic DNA was extracted from these cells with the SMITEST EX-R&D DNA extraction kit (Medical and Biological Laboratories, Co., Ltd, Nagoya, Japan). The genotypes of rs2074388 and rs2074379 variants of ALPK1 were determined at G&G Science Co., Ltd. (Fukushima, Japan) by the multiplex bead-based Luminex assay, a method that combines polymerase chain reaction (PCR) and sequence-specific oligonucleotide probes with suspension array technology (Luminex, Austin, TX, USA). Genotyping involved PCR amplification, hybridization, streptavidin-phycoerythrin reaction and measurement of fluorescence. The genotyping methodology was previously described in detail (14, 17) .
Materials and methods

Study
Statistical analysis. Quantitative data were compared between subjects with type 2 DM and controls using the unpaired Student's t-test and categorical data were compared using the Chi-square test. The allele frequencies were estimated with the gene-counting method and the Chi-square test was used to identify departures from Hardy-Weinberg equilibrium. Genotype distributions and allele frequencies of the rs2074388 and rs2074379 variants of ALPK1 were compared between subjects with type 2 DM and controls using the Chi-square test. A multivariable logistic regression analysis was performed with type 2 DM as a dependent variable and independent variables including age, gender (0, female; 1, male), body mass index, smoking status (0, non-smoker; 1, current or former smoker) and ALPK1 genotype; the P-values, odds ratios and 95% confidence intervals were calculated. The ALPK1 genotype was assessed according to dominant (0, wild-type homozygote; 1, heterozygote and variant homozygote) and recessive (0, wild-type homozygote and heterozygote; 1, variant homozygote) genetic models. We investigated the linkage disequilibrium between the rs2074388 and rs2074379 variants of ALPK1 and the association of the haplotypes of these polymorphisms to type 2 DM. P<0.05 was considered to indicate statistically significant differences. Statistical significance was assessed using two-sided tests performed with JMP Genomics software, version 6.0 (SAS Institute, Cary, NC, USA). Linkage disequilibrium and haplotype analysis of these polymorphisms were performed with SNPAlyze software, version 6 (Dynacom Co., Ltd., Yokohama, Japan).
Results
Subject characteristics. The baseline characteristics of the subjects are presented in Table I . Age, the frequency of male gender, body mass index and the prevalence of smoking, hypertension, dyslipidemia and chronic kidney disease were higher among subjects with type 2 DM compared to controls.
Comparison of genotype distributions and allele frequencies.
The comparison of genotype distributions or allele frequencies using the Chi-square test revealed that the rs2074388 and rs2074379 variants of ALPK1 were significantly associated with type 2 DM (P<0.05) ( Table II) . The genotype distributions of the two polymorphisms were in Hardy-Weinberg equilibrium among subjects with type 2 DM and controls.
Multivariable logistic regression analysis.
A multivariable logistic regression analysis with adjustment for age, gender, body mass index and smoking status revealed that rs2074388 (dominant model) and rs2074379 (dominant model) were significantly associated with type 2 DM, with the G alleles of the two polymorphisms representing risk factors for this disease (Table III) .
Dominant Recessive ---------------------------------------------------------------------------------------------------------------------------------------------------
Frequency ---------------------------------------------------------
Haplotype analysis. As the rs2074388 and rs2074379 variants of ALPK1 were in linkage disequilibrium [standard linkage disequilibrium coefficient (r 2 )=0.9908, P<0.0001], we performed a haplotype analysis for these polymorphisms. That analysis revealed that the frequency of the major haplotype, A (rs2074388)-A (rs2074379), was significantly lower (P<0.05), whereas that of the minor haplotype G-G was significantly higher in subjects with type 2 DM compared to controls (Table IV) .
Association of ALPK1 polymorphisms with plasma glucose and hemoglobin A 1c. Finally, we assessed the association of rs2074388 or rs2074379 to fasting plasma glucose level or blood hemoglobin A 1c content among all individuals, or individuals not on antidiabetic medication. There were no significant differences in the fasting plasma glucose level or blood hemoglobin A 1c content among the of rs2074388 or rs2074379 genotypes (data not shown).
Discussion
We previously demonstrated that ALPK1 is a susceptibility locus for chronic kidney disease in individuals with DM by a GWAS (14) . In this study, we demonstrated that the rs2074388 and rs2074379 variants of ALPK1 were significantly associated with the prevalence of type 2 DM in community-dwelling Japanese individuals, with the G alleles of the two polymorphisms representing risk factors for this disease.
ALPK1 is a member of a newly discovered protein kinase family that exhibits no sequence homology to the conventional protein kinases (18) . It functions in apical transport by phosphorylating myosin-1a and is a putative candidate for the regulation of intracellular trafficking processes by phosphorylation (19) . ALPK1 may act synergistically with monosodium urate monohydrate crystals in promoting the production of proinflammatory cytokines through the activation of nuclear factor-κB and mitogen-activated protein kinase (ERK1̸2 and p38) signaling in cultured HEK293 cells, suggesting that ALPK1 may contribute to the inflammatory process associated with the development of gout (20) .
Impaired insulin secretion and increased insulin resistance are key components of type 2 DM (21) . Although the contributions of these factors to the onset and progression of type 2 DM may differ between Caucasian and Asian populations, both factors are essential for the diagnostic and therapeutic strategies of type 2 DM (22) . Recent studies demonstrated that proinflammatory cytokines (interleukin-1β and tumor necrosis factor) exert deleterious effects on insulin secretion and insulin resistance (23, 24) . In addition, signal pathways activated by proinflammatory cytokines, such as nuclear factor-κB signaling, were shown to be responsible for these conditions (25) . As chronic inflammation may be an important factor in the development of type 2 DM, the effects of the rs2074388 or rs2074379 variants of ALPK1 on the acceleration of the inflammatory process may account for their association with type 2 DM.
Although the rs2074388 and rs2074379 variants of ALPK1 were significantly associated with the prevalence of type 2 DM, either polymorphism was not associated with fasting plasma glucose level or blood hemoglobin A 1c content among all individuals or individuals not on antidiabetic medication. Although the reason for this discrepancy has not been fully elucidated, there are possible explanations: i) the number of subjects with type 2 DM not on antidiabetic medication was limited; ii) information regarding drug compliance obtained by a questionnaire was incomplete; and iii) either polymorphism was not associated with fasting plasma glucose level among control individuals.
Our study had certain limitations: i) as the results of the present study were not replicated, validation of our findings may require their replication with other independent subject panels or ethnic groups; ii) it is possible that rs2074388 or rs2074379 are in linkage disequilibrium with other polymorphisms in the same gene or in other nearby genes that are actually responsible for the development of type 2 DM; iii) although the rs2074388 and rs2074379 variants of ALPK1 were significantly associated with the prevalence of type 2 DM, either polymorphism was not associated with fasting plasma glucose level or blood hemoglobin A 1c content; and iv) the functional relevance of the rs2074388 or rs2074379 variants of ALPK1 to the pathogenesis of type 2 DM has not been determined.
In conclusion, our results suggest that ALPK1 is a susceptibility gene for type 2 DM in community-dwelling Japanese individuals. Determination of the genotypes for the polymorphisms of ALPK1 may prove informative for the assessment of the genetic risk for type 2 DM in the Japanese population.
